The numbers of obese people and diabetic patients are ever increasing. Obesity and diabetes are high-risk conditions for chronic diseases, including certain types of cancer, such as colorectal cancer (CRC). The aim of this study was to develop a novel animal model in order to clarify the pathobiology of CRC development in obese and diabetic patients. We developed an animal model of obesity and colorectal cancer by breeding the C57BL/KsJ- db /db (db/db) mouse, an animal model of obesity and type II diabetes, and the C57BL/6J- ApcMin/+ (Min/+) mouse, a model of familial adenomatous polyposis. At 15 weeks of age, the N9 backcross generation of C57BL/KsJ- db /db- ApcMin/+ (db/db-Min/+) mice developed an increased incidence and multiplicity of adenomas in the intestinal tract when compared to the db/m-Min/+ and m/m-Min/+ mice. Blood biochemical profile showed significant increases in insulin (8.3-fold to 11.7-fold), cholesterol (1.2-fold to 1.7-fold), and triglyceride (1.2-fold to 1.3-fold) in the db/db-Min/+ mice, when compared to those of the db/m-Min/+ and m/m-Min/+ mice. Increases (1.4-fold to 2.6-fold) in RNA levels of insulin-like growth factor (IGF)-1, IRF-1R, and IGF-2 were also observed in the db/db-Min/+ mice. These results suggested that the IGFs, as well as hyperlipidemia and hyperinsulinemia, promoted adenoma formation in the db/db-Min/+ mice. Our results thus suggested that the db/db-Min/+ mice should be invaluable for studies on the pathogenesis of CRC in obese and diabetes patients and the therapy and prevention of CRC in these patients.
LeRoith, D.; Novosyadlyy, R.; Gallagher, E.J.; Lann, D.; Vijayakumar, A.; Yakar, S. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp. Clin. Endocrinol. Diabetes 2008, 116, S4–S6.
Yamada, Y.; Hata, K.; Hirose, Y.; Hara, A.; Sugie, S.; Kuno, T.; Yoshimi, N.; Tanaka, T.; Mori, H. Microadenomatous lesions involving loss of Apc heterozygosity in the colon of adult Apc(Min/+) mice. Cancer Res 2002, 62, 6367–6370.
Corpet, D.E.; Pierre, F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur. J. Cancer 2005, 41, 1911–1922.
Niho, N.; Takahashi, M.; Shoji, Y.; Takeuchi, Y.; Matsubara, S.; Sugimura, T.; Wakabayashi, K. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand. Cancer Sci 2003, 94, 960–964.
Shimizu, M.; Shirakami, Y.; Iwasa, J.; Shiraki, M.; Yasuda, Y.; Hata, K.; Hirose, Y.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Clin. Cancer Res 2009, 15, 3068–3075.
Mutoh, M.; Akasu, T.; Takahashi, M.; Niho, N.; Yoshida, T.; Sugimura, T.; Wakabayashi, K. Possible involvement of hyperlipidemia in increasing risk of colorectal tumor development in human familial adenomatous polyposis. Jpn. J. Clin. Oncol 2006, 36, 166–171.
Sturmer, T.; Buring, J.E.; Lee, I.M.; Gaziano, J.M.; Glynn, R.J. Metabolic abnormalities and risk for colorectal cancer in the physicians’ health study. Cancer Epidemiol. Biomarkers Prev 2006, 15, 2391–2397.
Tabuchi, M.; Kitayama, J.; Nagawa, H. Hyperglycemia and hypertriglyceridemia may associate with the adenoma-carcinoma transition in colorectal epithelial cells. J. Gastroenterol. Hepatol 2008, 23, 985–987.
Takahashi, H.; Yoneda, K.; Tomimoto, A.; Endo, H.; Fujisawa, T.; Iida, H.; Mawatari, H.; Nozaki, Y.; Ikeda, T.; Akiyama, T.; Yoneda, M.; Inamori, M.; Abe, Y.; Saito, S.; Nakajima, A.; Nakagama, H. Life style-related diseases of the digestive system: Colorectal cancer as a life style-related disease: From carcinogenesis to medical treatment. J. Pharmacol. Sci 2007, 105, 129–132.
Niho, N.; Takahashi, M.; Kitamura, T.; Shoji, Y.; Itoh, M.; Noda, T.; Sugimura, T.; Wakabayashi, K. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003, 63, 6090–6095.
Niho, N.; Mutoh, M.; Takahashi, M.; Tsutsumi, K.; Sugimura, T.; Wakabayashi, K. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proc. Natl. Acad. Sci. USA 2005, 102, 2970–2974.
Endo, H.; Hosono, K.; Uchiyama, T.; Sakai, E.; Sugiyama, M.; Takahashi, H.; Nakajima, N.; Wada, K.; Takeda, K.; Nakagama, H.; Nakajima, A. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut 2011, 60, 1363–1371.